248 related articles for article (PubMed ID: 18488877)
1. Raloxifene for older women: a review of the literature.
Hansdóttir H
Clin Interv Aging; 2008; 3(1):45-50. PubMed ID: 18488877
[TBL] [Abstract][Full Text] [Related]
2. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
Cranney A; Adachi JD
Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
[TBL] [Abstract][Full Text] [Related]
3. Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.
Ko SS; Jordan VC
Expert Opin Pharmacother; 2011 Mar; 12(4):657-74. PubMed ID: 21294695
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene: a review of its use in postmenopausal osteoporosis.
Clemett D; Spencer CM
Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
[TBL] [Abstract][Full Text] [Related]
5. Raloxifene: recent information on skeletal and non-skeletal effects.
Gluck O; Maricic M
Curr Opin Rheumatol; 2002 Jul; 14(4):429-32. PubMed ID: 12118180
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
7. Selective estrogen-receptor modulators.
Cosman F
Clin Geriatr Med; 2003 May; 19(2):371-9. PubMed ID: 12916292
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for raloxifene use in daily clinical practice in the Swiss setting.
Lippuner K; Buchard PA; De Geyter C; Imthurn B; Lamy O; Litschgi M; Luzuy F; Schiessl K; Stute P; Birkhäuser M
Eur Spine J; 2012 Dec; 21(12):2407-17. PubMed ID: 22739699
[TBL] [Abstract][Full Text] [Related]
9. Prevention and treatment of osteoporosis in women with breast cancer.
Mincey BA; Moraghan TJ; Perez EA
Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
[TBL] [Abstract][Full Text] [Related]
10. Review of raloxifene and its clinical applications in osteoporosis.
Maricic M; Gluck O
Expert Opin Pharmacother; 2002 Jun; 3(6):767-75. PubMed ID: 12036416
[TBL] [Abstract][Full Text] [Related]
11. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene: a review of its use in the prevention of invasive breast cancer.
Moen MD; Keating GM
Drugs; 2008; 68(14):2059-83. PubMed ID: 18778124
[TBL] [Abstract][Full Text] [Related]
13. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.
Lippman ME; Krueger KA; Eckert S; Sashegyi A; Walls EL; Jamal S; Cauley JA; Cummings SR
J Clin Oncol; 2001 Jun; 19(12):3111-6. PubMed ID: 11408508
[TBL] [Abstract][Full Text] [Related]
14. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.
Muchmore DB
Oncologist; 2000; 5(5):388-92. PubMed ID: 11040275
[TBL] [Abstract][Full Text] [Related]
15. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
[TBL] [Abstract][Full Text] [Related]
16. The evolution of selective estrogen receptor modulators in osteoporosis therapy.
Hadji P
Climacteric; 2012 Dec; 15(6):513-23. PubMed ID: 22853318
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of raloxifene hydrochloride.
Saitta A; Morabito N; Frisina N; Cucinotte D; Corrado F; D'Anna R; Altavilla D; Squadrito G; Minutoli L; Arcoraci V; Cancellieri F; Squadrito F
Cardiovasc Drug Rev; 2001; 19(1):57-74. PubMed ID: 11314601
[TBL] [Abstract][Full Text] [Related]
18. Raloxifene hydrochloride.
Snyder KR; Sparano N; Malinowski JM
Am J Health Syst Pharm; 2000 Sep; 57(18):1669-75; quiz 1676-8. PubMed ID: 11006795
[TBL] [Abstract][Full Text] [Related]
19. [The role of raloxifene (Evista) in the treatment and prevention of postmenopausal osteoporosis].
Korsić M
Reumatizam; 2003; 50(2):55-7. PubMed ID: 15098379
[TBL] [Abstract][Full Text] [Related]
20. Medical treatment of vertebral osteoporosis.
Lippuner K
Eur Spine J; 2003 Oct; 12 Suppl 2(Suppl 2):S132-41. PubMed ID: 13680313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
